Siew Pheng Lim

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5925960/publications.pdf

Version: 2024-02-01

74 papers	5,608 citations	61945 43 h-index	79644 73 g-index
76 all docs	76 docs citations	76 times ranked	4469 citing authors

#	Article	IF	Citations
1	NITD-688, a pan-serotype inhibitor of the dengue virus NS4B protein, shows favorable pharmacokinetics and efficacy in preclinical animal models. Science Translational Medicine, 2021, 13, .	5.8	43
2	A Cyclic Phosphoramidate Prodrug of 2â€²-Deoxy-2â€²-Fluoro-2â€²- C -Methylguanosine for the Treatment of Dengue Virus Infection. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	4
3	Two RNA Tunnel Inhibitors Bind in Highly Conserved Sites in Dengue Virus NS5 Polymerase: Structural and Functional Studies. Journal of Virology, 2020, 94, .	1.5	17
4	Editorial: Viral Evasion Mechanisms of the Host Response. Frontiers in Cellular and Infection Microbiology, 2020, 10, 90.	1.8	0
5	NS5 from Dengue Virus Serotype 2 Can Adopt a Conformation Analogous to That of Its Zika Virus and Japanese Encephalitis Virus Homologues. Journal of Virology, 2019, 94, .	1.5	31
6	Dengue drug discovery: Progress, challenges and outlook. Antiviral Research, 2019, 163, 156-178.	1.9	71
7	Discovery of Potent Non-nucleoside Inhibitors of Dengue Viral RNA-Dependent RNA Polymerase from Fragment Screening and Structure-Guided Design. Advances in Experimental Medicine and Biology, 2018, 1062, 187-198.	0.8	16
8	The Dengue Virus Replication Complex: From RNA Replication to Protein-Protein Interactions to Evasion of Innate Immunity. Advances in Experimental Medicine and Biology, 2018, 1062, 115-129.	0.8	45
9	Structure-activity relationship of uridine-based nucleoside phosphoramidate prodrugs for inhibition of dengue virus RNA-dependent RNA polymerase. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2324-2327.	1.0	19
10	Antiviral Nucleotide Incorporation by Recombinant Human Mitochondrial RNA Polymerase Is Predictive of Increased In Vivo Mitochondrial Toxicity Risk. Antimicrobial Agents and Chemotherapy, 2016, 60, 7077-7085.	1.4	18
11	Discovery of Potent Non-Nucleoside Inhibitors of Dengue Viral RNA-Dependent RNA Polymerase from a Fragment Hit Using Structure-Based Drug Design. Journal of Medicinal Chemistry, 2016, 59, 3935-3952.	2.9	70
12	A Conserved Pocket in the Dengue Virus Polymerase Identified through Fragment-based Screening. Journal of Biological Chemistry, 2016, 291, 8541-8548.	1.6	55
13	Potent Allosteric Dengue Virus NS5 Polymerase Inhibitors: Mechanism of Action and Resistance Profiling. PLoS Pathogens, 2016, 12, e1005737.	2.1	124
14	Identifying Initiation and Elongation Inhibitors of Dengue Virus RNA Polymerase in a High-Throughput Lead-Finding Campaign. Journal of Biomolecular Screening, 2015, 20, 153-163.	2.6	21
15	Molecular basis for specific viral RNA recognition and 2â€²-O-ribose methylation by the dengue virus nonstructural protein 5 (NS5). Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14834-14839.	3.3	89
16	A Crystal Structure of the Dengue Virus NS5 Protein Reveals a Novel Inter-domain Interface Essential for Protein Flexibility and Virus Replication. PLoS Pathogens, 2015, 11, e1004682.	2.1	180
17	The dengue virus NS5 protein as a target for drug discovery. Antiviral Research, 2015, 119, 57-67.	1.9	168
18	Stabilization of dengue virus polymerase in de novo initiation assay provides advantages for compound screening. Antiviral Research, 2015, 119, 36-46.	1.9	15

#	Article	IF	Citations
19	Flexibility of NS5 Methyltransferase-Polymerase Linker Region Is Essential for Dengue Virus Replication. Journal of Virology, 2015, 89, 10717-10721.	1.5	41
20	Polymerases of hepatitis C viruses and flaviviruses: Structural and mechanistic insights and drug development. Antiviral Research, 2014, 105, 8-16.	1.9	58
21	Activation of Peripheral Blood Mononuclear Cells by Dengue Virus Infection Depotentiates Balapiravir. Journal of Virology, 2014, 88, 1740-1747.	1.5	60
22	Flavivirus RNA methylation. Journal of General Virology, 2014, 95, 763-778.	1.3	107
23	Detection and Quantification of Flavivirus NS5 Methyl-Transferase Activities. Methods in Molecular Biology, 2013, 1030, 249-268.	0.4	5
24	Serotype-specific Differences in Dengue Virus Non-structural Protein 5 Nuclear Localization. Journal of Biological Chemistry, 2013, 288, 22621-22635.	1.6	76
25	A Crystal Structure of the Dengue Virus Non-structural Protein 5 (NS5) Polymerase Delineates Interdomain Amino Acid Residues That Enhance Its Thermostability and de Novo Initiation Activities. Journal of Biological Chemistry, 2013, 288, 31105-31114.	1.6	74
26	Ten years of dengue drug discovery: Progress and prospects. Antiviral Research, 2013, 100, 500-519.	1.9	310
27	West Nile Virus Drug Discovery. Viruses, 2013, 5, 2977-3006.	1.5	42
28	Conformational Flexibility of the Dengue Virus RNA-Dependent RNA Polymerase Revealed by a Complex with an Inhibitor. Journal of Virology, 2013, 87, 5291-5295.	1.5	89
29	2â€²-O Methylation of Internal Adenosine by Flavivirus NS5 Methyltransferase. PLoS Pathogens, 2012, 8, e1002642.	2.1	125
30	Small Molecule Inhibitors That Selectively Block Dengue Virus Methyltransferase. Journal of Biological Chemistry, 2011, 286, 6233-6240.	1.6	147
31	Dengue protease activity: the structural integrity and interaction of NS2B with NS3 protease and its potential as a drug target. Bioscience Reports, 2011, 31, 399-409.	1.1	46
32	Strategies for development of dengue virus inhibitors. Antiviral Research, 2010, 85, 450-462.	1.9	240
33	Higher catalytic efficiency of N-7-methylation is responsible for processive N-7 and 2â€²-O methyltransferase activity in dengue virus. Virology, 2010, 402, 52-60.	1.1	55
34	Biochemical and genetic characterization of dengue virus methyltransferase. Virology, 2010, 405, 568-578.	1.1	91
35	Crystal Structure of the Dengue Virus Methyltransferase Bound to a 5â€²-Capped Octameric RNA. PLoS ONE, 2010, 5, e12836.	1.1	34
36	Structural and Functional Analyses of a Conserved Hydrophobic Pocket of Flavivirus Methyltransferase. Journal of Biological Chemistry, 2010, 285, 32586-32595.	1.6	52

#	Article	IF	Citations
37	Novel Inhibitors of Dengue Virus Methyltransferase: Discovery by in Vitro-Driven Virtual Screening on a Desktop Computer Grid. Journal of Medicinal Chemistry, 2010, 53, 1483-1495.	2.9	76
38	Discovery of a Non-Peptidic Inhibitor of West Nile Virus NS3 Protease by High-Throughput Docking. PLoS Neglected Tropical Diseases, 2009, 3, e356.	1.3	71
39	NMR Analysis of the Dynamic Exchange of the NS2B Cofactor between Open and Closed Conformations of the West Nile Virus NS2B-NS3 Protease. PLoS Neglected Tropical Diseases, 2009, 3, e561.	1.3	75
40	NMR study of complexes between low molecular mass inhibitors and the West Nile virus NS2Bâ€“NS3 protease. FEBS Journal, 2009, 276, 4244-4255.	2.2	35
41	A fluorescence quenching assay to discriminate between specific and nonspecific inhibitors of dengue virus protease. Analytical Biochemistry, 2009, 395, 195-204.	1.1	92
42	Flaviviral Protease Inhibitors Identified by Fragment-Based Library Docking into a Structure Generated by Molecular Dynamics. Journal of Medicinal Chemistry, 2009, 52, 4860-4868.	2.9	77
43	Insights into RNA unwinding and ATP hydrolysis by the flavivirus NS3 protein. EMBO Journal, 2008, 27, 3209-3219.	3.5	221
44	Towards the design of antiviral inhibitors against flaviviruses: The case for the multifunctional NS3 protein from Dengue virus as a target. Antiviral Research, 2008, 80, 94-101.	1.9	184
45	A scintillation proximity assay for dengue virus NS5 2â€²-O-methyltransferaseâ€”kinetic and inhibition analyses. Antiviral Research, 2008, 80, 360-369.	1.9	56
46	Mutagenesis of the Dengue Virus Type 2 NS5 Methyltransferase Domain. Journal of Biological Chemistry, 2008, 283, 19410-19421.	1.6	65
47	Finding New Medicines for Flaviviral Targets. Novartis Foundation Symposium, 2008, , 102-119.	1.2	34
48	Yellow fever virus NS3 protease: peptide-inhibition studies. Journal of General Virology, 2007, 88, 2223-2227.	1.3	29
49	Cell-Free Transcription/Translation from PCR-Amplified DNA for High-Throughput NMR Studies. Angewandte Chemie - International Edition, 2007, 46, 3356-3358.	7.2	69
50	Construction and characterization of a stable subgenomic dengue virus type 2 replicon system for antiviral compound and siRNA testing. Antiviral Research, 2007, 76, 222-231.	1.9	86
51	Peptide Inhibitors of West Nile NS3 Protease:â€‰ SAR Study of Tetrapeptide Aldehyde Inhibitors. Journal of Medicinal Chemistry, 2006, 49, 6585-6590.	2.9	79
52	Purification and crystallization of dengue and West Nile virus NS2Bâ€“NS3 complexes. Acta Crystallographica Section F: Structural Biology Communications, 2006, 62, 157-162.	0.7	18
53	Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nature Structural and Molecular Biology, 2006, 13, 372-373.	3.6	478
54	Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 40-43.	1.0	142

#	Article	IF	Citations
55	Peptide inhibitors of dengue virus NS3 protease. Part 1: Warhead. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 36-39.	1.0	152
56	Use of an in vitro Model and Yeast Two-Hybrid System to Investigate the Pathogenesis of Hepatitis C. Intervirology, 2006, 49, 44-50.	1.2	5
57	Finding new medicines for flaviviral targets. Novartis Foundation Symposium, 2006, 277, 102-14; discussion 114-9, 251-3.	1.2	21
58	Functional Profiling of Recombinant NS3 Proteases from All Four Serotypes of Dengue Virus Using Tetrapeptide and Octapeptide Substrate Libraries. Journal of Biological Chemistry, 2005, 280, 28766-28774.	1.6	219
59	Cellular RNA Helicase p68 Relocalization and Interaction with the Hepatitis C Virus (HCV) NS5B Protein and the Potential Role of p68 in HCV RNA Replication. Journal of Virology, 2004, 78, 5288-5298.	1.5	111
60	Differential polarization of immune responses by co-administration of antigens with chemokines. Vaccine, 2004, 23, 546-554.	1.7	17
61	CD81 engineered with endocytotic signals mediates HCV cell entry: implications for receptor usage by HCV in vivo. Virology, 2003, 308, 250-269.	1.1	21
62	An anti-HIV-1 gp120 antibody expressed as an endocytotic transmembrane protein mediates internalization of HIV-1. Virology, 2003, 315, 80-92.	1.1	6
63	Expression of a Full-Length Hepatitis C Virus cDNA Up-Regulates the Expression of CC Chemokines MCP-1 and RANTES. Virology, 2002, 303, 253-277.	1.1	56
64	Inducible System in Human Hepatoma Cell Lines for Hepatitis C Virus Production. Virology, 2002, 303, 79-99.	1.1	16
65	Arylalkylidene rhodanine with bulky and hydrophobic functional group as selective HCV NS3 protease inhibitor. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 91-94.	1.0	154
66	The Hepatitis C Virus Core Protein Interacts with NS5A and Activates Its Caspase-Mediated Proteolytic Cleavage. Virology, 2001, 290, 224-236.	1.1	51
67	Identification and molecular characterisation of the complete genome of a Singapore isolate of hepatitis C virus: sequence comparison with other strains and phylogenetic analysis. Virus Genes, 2001, 23, 89-95.	0.7	12
68	Mutations That Affect Dimer Formation and Helicase Activity of the Hepatitis C Virus Helicase. Journal of Virology, 2001, 75, 205-214.	1.5	35
69	Cloning Trap for Signal Peptide Sequences. BioTechniques, 2000, 28, 124-130.	0.8	6
70	The Human Immunodeficiency Virus Type 1 Tat Protein Up-Regulates the Promoter Activity of the Beta-Chemokine Monocyte Chemoattractant Protein 1 in the Human Astrocytoma Cell Line U-87 MG: Role of SP-1, AP-1, and NF-Î²B Consensus Sites. Journal of Virology, 2000, 74, 1632-1640.	1.5	90
71	The Î²7 integrin gene (Itgb-7) promoter is responsive to TGF-Î²1: defining control regions. Immunogenetics, 1998, 48, 184-195.	1.2	50
72	A Novel Extracellular Domain Variant of the Human Integrin Î±7 Subunit Generated by Alternative Intron Splicing. Biochemical and Biophysical Research Communications, 1998, 243, 317-325.	1.0	17

#	Article	IF	Citations
73	Structural and functional analysis of a promoter of the human granulin/epithelin gene. Biochemical Journal, 1996, 319, 441-447.	1.7	37
74	Characterization of a novel IRF-1-deficient mutant cell line. Immunogenetics, 1994, 39, 168-77.	1.2	7